[go: up one dir, main page]

AR060440A1 - Agonistas receptores de eritropoietina - Google Patents

Agonistas receptores de eritropoietina

Info

Publication number
AR060440A1
AR060440A1 ARP070101570A ARP070101570A AR060440A1 AR 060440 A1 AR060440 A1 AR 060440A1 AR P070101570 A ARP070101570 A AR P070101570A AR P070101570 A ARP070101570 A AR P070101570A AR 060440 A1 AR060440 A1 AR 060440A1
Authority
AR
Argentina
Prior art keywords
erythropoietin receptor
receptor agonists
antibodies
erythropoietin
fix
Prior art date
Application number
ARP070101570A
Other languages
English (en)
Inventor
Luis Borges
Randal R Ketchem
Ai Ching Limb
Christopher Mehlin
Hongxing Zhou
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR060440A1 publication Critical patent/AR060440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proveen anticuerpos que fijan el Receptor de eritropoietina. También se proveen los métodos para realizar y utilizar dichos anticuerpos. También se proveen Kits que contienen dichos anticuerpos.
ARP070101570A 2006-04-14 2007-04-13 Agonistas receptores de eritropoietina AR060440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79217406P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
AR060440A1 true AR060440A1 (es) 2008-06-18

Family

ID=38610179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101570A AR060440A1 (es) 2006-04-14 2007-04-13 Agonistas receptores de eritropoietina

Country Status (10)

Country Link
US (1) US20080124340A1 (es)
EP (1) EP2007812A2 (es)
JP (1) JP2009533057A (es)
AR (1) AR060440A1 (es)
AU (1) AU2007238704A1 (es)
CA (1) CA2649384A1 (es)
MX (1) MX2008013201A (es)
PE (1) PE20080187A1 (es)
TW (1) TW200808822A (es)
WO (1) WO2007120766A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2614260T3 (es) 2000-05-26 2017-05-30 Immunex Corporation Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos
US20100203047A1 (en) * 2007-10-05 2010-08-12 University Of Maryland, Baltimore Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal
CN102282174B (zh) * 2009-01-15 2014-02-26 弗·哈夫曼-拉罗切有限公司 抗人epo受体的抗体
US8460660B2 (en) 2009-03-24 2013-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
CN105452546B (zh) * 2012-08-31 2018-05-29 斯克利普斯研究院 与真核细胞调节剂相关的方法和组合物
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
CA2943361A1 (en) 2014-03-28 2015-10-01 New York University Fgf23 fusion proteins
WO2016018883A1 (en) * 2014-07-29 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Tuning dimeric receptor signaling with extracellular ligands that alter receptor orientation and proximity upon binding
EP3334842B1 (en) 2015-08-12 2022-03-02 Novartis AG Methods of treating ophthalmic disorders
AU2016341409B2 (en) * 2015-10-23 2021-02-25 Apogenix Ag Single-chain CD27-receptor agonist proteins
WO2017189588A1 (en) * 2016-04-25 2017-11-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind stat3
US20230399418A1 (en) * 2020-11-10 2023-12-14 The Scripps Research Institute Antibodies for opioid treatments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US6998124B1 (en) * 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
AU2007238705A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies

Also Published As

Publication number Publication date
US20080124340A1 (en) 2008-05-29
AU2007238704A1 (en) 2007-10-25
EP2007812A2 (en) 2008-12-31
TW200808822A (en) 2008-02-16
WO2007120766A3 (en) 2008-05-29
MX2008013201A (es) 2008-10-22
JP2009533057A (ja) 2009-09-17
WO2007120766A2 (en) 2007-10-25
PE20080187A1 (es) 2008-03-10
CA2649384A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AR060440A1 (es) Agonistas receptores de eritropoietina
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CU20110029A7 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
CR20150088A (es) Anticuerpos anti-notch1 nrr
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
CR10612A (es) Anticuerpo especifico prlr y sus usos
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR11274A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CR11361A (es) Moleculas y metodos para modular el componente de complemento
CR9786A (es) Compuestos de bencimidazol-tiofeno
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
BRPI0702163A (pt) composições de toner e métodos
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
ES2572368T3 (es) Tratamiento de la artrosis
EA200801402A1 (ru) Карбаматные соединения в качестве агонистов рецептора 5-нт
CR20110555A (es) Anticuerpos anti-fgfr3 y métosos que los utilizan

Legal Events

Date Code Title Description
FA Abandonment or withdrawal